Diagnostic values of microRNA 27a in breast cancer patients
Egyptian journal of Immunology · 2021
DOI: 10.55133/eji.280313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian journal of Immunology, 2021. Verfasst von Mohamed Seddik und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer is one of the most malignant tumors in women across the globe. Diagnosis of breast cancer at early stages is essential to improve treatment outcomes and decrease mortality rates. There is a pressing need for new non-invasive biomarkers to improve early diagnosis of breast cancer. This study aims to assess plasma miR-27a for the early diagnosis of breast cancer. miR-27a was evaluated in a total of 95 blood samples, 40 newly diagnosed cancer patients, 20 patients with benign breast lesions, 20 females with positive family history for breast cancer and 15 apparently healthy controls, using quantitative real time polymerase chain reaction. Our results exhibited significantly higher expression level of plasma miR-27a in breast cancer patients (median= 8.3 and 19 fold change for early and late stages respectively) compared to controls, high risk group and benign group with (P
Zitieren
APA
Seddik, M., Osman, O., Jabir, M., Abdelrahman, E., & Nigm, D. (2021). Diagnostic values of microRNA 27a in breast cancer patients. Egyptian journal of Immunology. https://doi.org/10.55133/eji.280313
Vancouver
Seddik M, Osman O, Jabir M, Abdelrahman E, Nigm D. Diagnostic values of microRNA 27a in breast cancer patients. Egyptian journal of Immunology. 2021. doi:10.55133/eji.280313
BibTeX
@article{Seddik2021,
author = {Seddik, Mohamed and Osman, Osama and Jabir, Murad and Abdelrahman, Eman and Nigm, Dalia},
title = {Diagnostic values of microRNA 27a in breast cancer patients},
journal = {Egyptian journal of Immunology},
year = {2021},
doi = {10.55133/eji.280313}
}
EUVIMED